Erudio Healtherudio.com
Drug
Catequentinib trials: what clinicians said in public
An HCP commentary report on 1 clinical trial studying catequentinib: ETER100. It covers what clinicians said in public about one trial, on podcasts, videos and posts, every statement linked to its source. Below them, 1 more trial with public commentary and no report yet.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| ETER100 NCT04523272 · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | first-line advanced renal cell carcinoma | Phase 3 | 44 | 4 | Focused | Nov 22, 2026 | Preview |
| No report yetTrials with public commentary we haven't built a report for. Size is an estimate of the verified statements the commentary we've indexed so far will yield; final coverage is set when we build the report, within 24 hours of your confirmed order. You never pay more than quoted: a report delivered at a smaller size costs that size's price. Some can also be requested as a free preview. | |||||||
| RCT-PAAG NCT06051851 · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School FocusedView → | first-line metastatic pancreatic adenocarcinoma | Phase 2 | Focused | View | |||